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Abstract This study aims to investigate the association
between prenatal exposure to terbutaline and other β2
adrenergic receptor (B2AR) agonists and autism spectrum
disorders (ASDs). The methodology used is a case–control
study among children born from 1995 to 1999 at Kaiser
Permanente Northern California hospitals. Cases (n=291)
were children with an ASD diagnosis; controls (n=284)
were children without ASDs, randomly sampled and
frequency-matched to cases on sex, birth year, and delivery
hospital. Exposure to B2AR agonists during 30 days prior
to conception and each trimester of pregnancy was
ascertained from prenatal medical records and health plan
databases. The frequency of exposure to any B2AR agonist
during pregnancy was similar for mothers of children with
ASD and mothers of controls (18.9% vs. 14.8%, P=0.19).
Exposure to B2AR agonists other than terbutaline was not
associated with an increased risk for ASDs. However,
terbutaline exposure for >2 days during the third trimester
was associated with more than a fourfold increased risk for
ASDs independent of indication although the limited
sample size resulted in an imprecise and nonsignificant
effect estimate (ORadj=4.4; 95% confidence interval, 0.8–
24.6). This analysis does not offer evidence linking B2AR
exposure in pregnancy with autism risk. However, exposure
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associated with an increased risk of autism. Should this
result be confirmed in larger samples, it would point to late
pregnancy as an etiologic window of interest in autism risk
factor research.
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Introduction
Key pathophysiologic changes observed in the brain of
autistic individuals provide compelling evidence that
autism begins during fetal development (Casanova 2007;
Bauman and Kemper 2005; Rodier 2000). While genetic
susceptibility undoubtedly underlies autism etiology in
many cases (Abrahams and Geschwind 2008), environ-
mental factors likely play a role as well (Cook and Scherer
2008). Evidence has recently emerged linking maternal
prenatal exposures such as illnesses, medications, environ-
mental toxins, and psychological stress with autism risk
(Connors et al. 2005; Roberts et al. 2007; Beversdorf et al.
2005; Croen et al. 2005).
Terbutaline, a β2 adrenergic receptor (B2AR) agonist,
has been used off-label for the past 30 years to treat preterm
labor. Terbutaline readily crosses the placenta and blood–
brain barrier (Bergman et al. 1984; Hsu et al. 1994; Slotkin
et al. 1994) and has been shown in animals to elicit
biochemical alterations and structural damage in the
immature brain during critical developmental periods
(Rhodes et al. 2004). When administered to rats at a
neurodevelopmental stage equivalent to the mid-second to
early third trimester in humans (Rice and Barone 2000),
terbutaline dysregulates function of the enzyme adenylyl
cyclase and leads to abnormal generation (excess and
deficiency) of the signaling molecule cyclic adenosine
monophosphate (cAMP) in different brain regions at
different stages of development (Rhodes et al. 2004; Slotkin
et al. 2001, 2003; Meyer et al. 2005). Terbutaline exposure
during this prenatal window results in changes in the rat
central nervous system similar to those found in autism
postmortem studies such as cerebellar abnormalities (delays
in synaptogenesis and reduction in Purkinje cell number),
deficient hippocampal development, and neuroimmune
activation (Rhodes et al. 2004; Zerrate et al. 2007; Bauman
and Kemper 1985; Vargas et al. 2005; Casanova et al.
2006). In humans, continuous administration of terbutaline
for 2 weeks or more between 16 and 36.5 weeks’ gestation
has been linked to concordance of autism spectrum
disorders (ASDs) in dizygotic twins (Connors et al. 2005).
The study by Connors et al. ascertained 36 dizygotic twin
pairs from autism clinics in which at least one twin had an
ASD diagnosis and found an association (relative risk=
2.28) between terbutaline exposure for more than 2 weeks
and concordance for ASDs. The relative risk increased to
4.4 (p=0.035) in those twin sets who were both male and
without a family history of ASDs.
Terbutaline and other B2AR agonists are Food and Drug
Administration (FDA) approved for the treatment of
asthma, one of the most common conditions that may
complicate pregnancy. The use of medications to control
asthma during pregnancy is still recommended since
uncontrolled asthma is associated with poor birth outcomes
(Bracken et al. 2003). Previously, we reported that a
diagnosis of asthma in the second trimester was associated
with a twofold increased risk of autism in the offspring
(Croen et al. 2005). While factors related to the underlying
disease process may put pregnant women with asthma at
higher risk for having a child on the autism spectrum, the
possibility that asthma treatment with B2AR agonists may
explain this link requires investigation.
We conducted a case–control study to investigate the
potential association between maternal exposure to terbuta-
line and other B2AR agonists during pregnancy and risk of
delivering an infant subsequently diagnosed with an ASD.
Materials and methods
Our study population was drawn from the Childhood Autism
Perinatal Study, a large case–control study examining pre-,
peri-, and neonatal risk factors for ASDs among the
membership of Kaiser Permanente of Northern California
(KPNC; Croen et al. 2005). KPNC is a group model
integrated health plan that provides care for over 3.2 million
northern California residents. The KPNC membership
represents approximately 30% of the insured population in
the region and is demographically similar to the residents of
the counties served by KPNC, except that the very poor and
very wealthy are underrepresented (Krieger 1992). Cases and
controls were identified from the cohort of infants born at a
KPNC facility between January 1995 and June 1999 who
remained KPNC members for at least 2 years following birth
(n=88,163).
Cases were defined as children with at least one
diagnosis of an ASD, including autism (International
Classification of Diseases 1999; ICD-9-CM code 299.0)
and Asperger’s Disorder or Pervasive Developmental
Disorder Not Otherwise Specified (ICD-9-CM code
299.8) recorded anytime between January 1995 and
December 2002 in KPNC outpatient clinical databases
(n=420). Children with fragile X syndrome (n=2),
tuberous sclerosis (n=0), or neurofibromatosis (n=0)were
excluded. One control per case was randomly selected
from the cohort of KPNC births without an ASD
308 J Neurodevelop Disord (2011) 3:307–315diagnosis, frequency matched to cases on sex, birth year,
and delivery hospital. Since we were interested in
examining characteristics of the mother in relation to
autism risk in the offspring, we randomly sampled one
child for inclusion for each woman who contributed two
children to the original study sample (13 case mothers, 5
control mothers). Only children whose mothers were
KPNC members with pharmacy benefits from at least
1 month before conception through the end of the
pregnancy were included (291 cases, 284 controls).
Women with pharmacy benefits during this time period
were very likely to have purchased all of their prescription
medications at a KPNC pharmacy.
Information on maternal exposure to B2AR agonists was
ascertained from the KPNC pharmacy database, which
records all dispensed prescriptions at KP pharmacies, and
abstracted from prenatal medical records using a standard-
ized form. All inpatient and outpatient prescriptions were
identified in the 30 days before conception through the end
of the pregnancy with the study child. B2AR agonists
included: Advair®, albuterol, Combivent®, Foradil®,
Maxair®, metaproterenol, Ritodrine®, Serevent®, terbutaline,
Tornalate®, and Xopenex® (Table 1). Only two B2AR
agonists have been used for tocolysis in the USA, ritodrine
and terbutaline. Terbutaline is the generic for Brethine,
Bricanyl, and Brethaire, all of which were searched in the
pharmacy database along with Ritodrine but only prescrip-
tions for terbutaline were found. Since generic terbutaline is
inexpensive and comes in a variety of forms for administra-
tion, it was the B2AR agonist in use for tocolysis during the
time period of this study. Inhalers, injections, and pills were
the only routes of administration included. Topical,
ophthalmic, and otic routes were excluded.
Four time periods of exposure were defined: preconcep-
tion (the 30 days prior to the last menstrual period (LMP)),
first trimester (in the 90 days post-LMP), second trimester
(90–180 days post-LMP), and third trimester (180 days
post-LMP to date of delivery). To account for possible
inaccuracies in LMP date, the preconception period was
included as a proxy for very early pregnancy exposure.
The date the prescription was dispensed and the number
of days supplied were used to determine exposure status
during each time period. Exposure during a given time
period was assumed if a prescription was dispensed during
the time period or the days supplied overlapped some
portion of the time period. Duration of exposure was
derived by summing the total number of days during
pregnancy for which a B2AR agonist was prescribed.
Maternal conditions that were indications for B2AR
agonists during pregnancy were identified from inpatient
and outpatient databases and abstracted from prenatal
records. Clinical indicators included asthma, preterm labor,
and conditions that predispose to preterm labor (bicornuate
uterus, cervical incompetence, multiple fibroids, hyperten-
sion, diabetes, anemia, bacterial vaginosis, pyelonephritis,
asymptomatic bacteriuria, chorioamnionitis, urinary tract
infection, and sexually transmitted diseases). Information
on several maternal and infant characteristics was obtained
from health plan and vital statistics databases.
Characteristics of cases and controls were compared
using contingency tables for categorical variables and
comparisons of means for continuous variables. Uncondi-
tional logistic regression analysis was conducted to estimate
relative risks of ASD associated with maternal use of B2AR
agonists during pregnancy. Separate models were run for all
B2AR agonists combined, terbutaline alone, and albuterol
alone, the two most frequently used B2AR agonists. For
each exposure definition, we examined time period of
exposure as well as duration of exposure. We defined
exposure duration categories based on the distribution of
days of exposure among the control group. For terbutaline,
most use was for 1 or 2 days, reflecting acute exposure, or
Table 1 B2AR agonists and
mimics included in analyses,
listed by indication
B2AR β2-adrenergic receptor
B2AR agonists Total (N=575)
n (%)
Asthma
Salmeterol xinafoate/fluticasone propionate (Advair®, Advair HFA®) 0 (0.00)
Albuterol, albuterol sulfate (Proventil®, Ventolin®, AccuNeb®) 47 (8.17)
Ipratropium bromide/albuterol sulfate (Combivent®) 0 (0.00)
Formoterol fumarate (Foradil®, Foradil Aerolizer®) 0 (0.00)
Pirbuterol acetate (Maxair®) 0 (0.00)
Metaproterenol, metaproterenol sulfate (Alupent®, Arm-a-med® (Metapro), Metaprel®) 2 (0.35)
Salmeterol xinafoate (Serevent®) 2 (0.35)
Levalbuterol HCL (Xopenex®) 0 (0.00)
Pre-term labor
Ritodrine, ritodrine hydrochloride 0 (0.00)
Terbutaline, terbutaline sulfate (Brethaire®, Breathair®, Brethine®) 55 (9.57)
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also examined exposure to terbutaline for ≥2 weeks, the
duration found to be associated with ASD concordance
among dizygotic twins in a previous study. For albuterol,
duration was dichotomized as >21 days vs. ≤21 days, the
cut-point representing the median length of exposure
among control mothers. Women with no prescriptions or
days supplied for any B2AR agonists for the entire period
from 30 days before conception through the end of
pregnancy were considered unexposed for all analyses.
Maternal and infant characteristics associated with maternal
exposure to B2AR agonists or case–control status were
treated as possible confounders and included as covariates
in multivariable models as were the matching variables. All
covariates were entered simultaneously into regression
models and all statistical tests were two-tailed. Study
procedures were approved by the KPNC Northern
California Institutional Review Board and the California
State Committee for the Protection of Human Subjects.
Results
Children with autism (n=291) were more likely than
controls(n=284) to be a twin or triplet, second born, weighing
<2,500 g at birth, and have a mother of older age and with
higher level of education (Table 2). Among controls, the
frequency of exposure to B2AR agonists during pregnancy
was higher among women carrying twins compared with
singletons (45.5% vs. 13.6%, P<0.01), women who delivered
preterm compared with term (29.4% vs. 13.9%, P=0.08), and
women who delivered low birth weight compared with
normal birth weight children (40.0% vs. 13.9%, P=0.02).
The prevalence of exposure to any B2AR agonist was
similar for the mothers of children with autism compared
with mothers of control children for the entire pregnancy
period (18.9% vs. 14.8%, P=0.19) as well as for each
trimester (Table 3). Albuterol was the most prevalent B2AR
agonist among mothers of both cases and controls during
the preconception period (3.1% vs. 2.1%, P=0.46), as well
as in the first (4.8% vs. 3.2%, P=0.31) and second (6.2%
vs. 4.9%, P=0.51) trimesters. Prevalence of exposure to
any B2AR agonist was highest in the third trimester for
both case and control mothers (14.1% vs. 12.0%, P=0.45).
Terbutaline accounted for the majority of thirdtrimester
exposures for both cases and controls (11.0% vs. 7.8%, P=
0.18) followed by albuterol (4.1% vs. 4.2%, P=0.95). After
controlling for covariates (birth order, plurality, maternal
age, maternal education, and gestational age) and matching
variables (gender, birth year, and delivery hospital), the risk
of delivering a child later diagnosed with an ASD was not
significantly elevated for women with any B2AR agonist
exposures during pregnancy (Table 3).
Table 2 Characteristics of the study population, Kaiser Permanente
Northern California births, 1995–1999
Characteristics No. (%) P value
a
ASD cases
(n=291)
Controls
(n=284)
Gender (male) 243 (83.51) 230 (80.99) 0.43
Plurality
Singleton 273 (93.81) 273 (96.13) 0.21
Twin or triplet 18 (6.19) 11 (3.87)
Birth order
First born 121 (41.58) 122 (42.96) 0.18
Second born 113 (38.83) 92 (32.39)
Third or later born 57 (19.59) 70 (24.65)
Maternal age
<20 3 (1.03) 8 (2.82) 0.14
20–24 25 (8.59) 29 (10.21)
25–29 64 (21.99) 79 (27.82)
30–34 104 (35.74) 99 (34.86)
35–39 84 (28.87) 60 (21.13)
≥40 11 (3.78) 9 (3.17)
Maternal education
<HS 10 (3.44) 18 (6.34) <0.001
HS 49 (16.84) 78 (27.46)
College 163 (56.01) 152 (53.52)
Post-graduate 68 (23.37) 34 (11.97)
Unknown 1 (0.34) 2 (0.70)
Maternal race/ethnicity
White, non-Hispanic 157 (53.95) 138 (48.59) 0.23
White, Hispanic 40 (13.75) 60 (21.13)
Black 27 (9.28) 24 (8.45)
Asian 28 (9.62) 24 (8.45)
Other 39 (13.4) 38 (13.38)
Gestational age
<37 Weeks 25 (8.59) 17 (5.99) 0.23
≥37 Weeks 266 (91.41) 267 (94.01)
Birthweight
<2,500 g 24 (8.25) 10 (3.52) 0.02
≥2,500 g 267 (91.75) 274 (96.48)
Parity
No previous births 126 (43.3) 118 (41.55) 0.03
One previous birth 114 (39.18) 91 (32.04)
Two or more previous births 51 (17.53) 75 (26.41)
Birth year
1995 85 (29.21) 75 (26.41) 0.81
1996 65 (22.34) 72 (25.35)
1997 59 (20.27) 57 (20.07)
1998 59 (20.27) 62 (21.83)
1999 23 (7.90) 18 (6.34)
HS high school
aChi-square test
310 J Neurodevelop Disord (2011) 3:307–315Women with terbutaline exposure for >2 days (N=
8 (3.2%) cases vs. N=2 (0.79%) controls) had a fourfold
increased risk of having a child subsequently diagnosed
with an ASD (ORadj=4.1; 95% confidence interval (CI),
0.7–22.4; Table 4). Among women with >2 days of
exposure to terbutaline (range, 5–48 days), the mean
(±SD) duration of exposure was 16.4 (12.1)days for cases
and 21 (15.6)days for controls. All women with >2 days of
exposure to terbutaline were exposed for this duration
during the third trimester. In addition to terbutaline
exposure at >2 days, one case mother had third trimester
exposure to albuterol, and two case mothers had second
trimester exposure to albuterol. Results were similar for
terbutaline exposure of 2 weeks or more (four cases, one
control; OR=4.3; 95% CI, 0.5–38.5). The risk of ASD was
not elevated among women with >21 days of exposure to
albuterol during pregnancy, (n=14 cases, n=11 controls;
ORadj=1.3; 95% CI, 0.5–3.2; Table 4). Albuterol exposure
of >21 days duration spanned all three trimesters of
pregnancy.
Among women who took any B2AR agonist at some
point during pregnancy, 30% of cases and 36% of controls
had a diagnosis of asthma during pregnancy and 53% of
cases and 43% of controls had a diagnosis of preterm labor.
Among women who were exposed to terbutaline during
pregnancy, 0 case mothers and 1 (4.5%) control mothers
had a diagnosis of asthma only, 28 (84.5%) of case mothers
and 18 (81.8%) of control mothers had a diagnosis of
preterm labor only, and 3 (9.1%) case mothers and no
control mothers had both asthma and preterm labor
diagnoses.
In order to explore the effect of terbutaline exposure on
autism risk independent of the effect of the indicating
condition, we first controlled for the indicating condition
via adjustment. Logistic regression models were fit including
both the treatment variable and indicating illness as predictor
variables. Controlling for indication, the risk of ASD
associated with terbutaline exposure for >2 days (ORadj=
4.4; 95% CI, 0.8–24.6) or ≥2 weeks (ORadj=4.7; 95% CI,
0.4–53.3) during the third trimester of pregnancy remained
Table 3 Odds ratios (ORs) and 95% confidence intervals (CIs) for autism spectrum disorders (ASDs) associated with prenatal exposure to B2AR
agonists
Exposure
a No. (%) P value
b Crude OR (95% CI) Adjusted OR (95% CI)
c Adjusted OR (95% CI)
d
ASD cases
(n=291)
Controls
(n=284)
Any B2AR agonist
e
Preconception period 9 (3.09) 6 (2.11) 0.46 1.6 (0.6–4.4) 1.9 (0.6–6.1) 2.0 (0.6–6.4)
Pregnancy period 55 (18.90) 42 (14.79) 0.19 1.4 (0.9–2.1) 1.1 (0.7–1.9) 1.2 (0.7–2.0)
First Trimester 15 (5.15) 10 (3.52) 0.34 1.6 (0.7–3.5) 1.4 (0.6–3.6) 1.6 (0.6–4.0)
Second Trimester 19 (6.53) 15 (5.28) 0.53 1.3 (0.7–2.7) 1.3 (0.6–2.8) 1.4 (0.6–3.1)
Third Trimester 41 (14.09) 34 (11.97) 0.45 1.3 (0.8–2.0) 1.0 (0.6–1.8) 1.1 (0.6–1.9)
Terbutaline
Preconception period 0 (0.00) 0 (0.00) –– –
Pregnancy period 33 (11.34) 22 (7.75) 0.14 1.6 (0.9–2.8) 1.2 (0.6–2.3) 1.2 (0.6–2.4)
First Trimester 1 (0.34) 0 (0.00) 0.32 –– –
Second Trimester 1 (0.34) 1 (0.35) 0.99 1.0 (0.1–16.7) 0.8 (0.0–29.1) 0.8 (0.0–31.8)
Third Trimester 32 (11.00) 22 (7.75) 0.18 1.5 (0.9–2.7) 1.2 (0.6–2.3) 1.2 (0.6–2.4)
Albuterol
Preconception period 9 (3.09) 6 (2.11) 0.46 1.6 (0.6–4.4) 1.9 (0.6–6.1) 2.0 (0.6–6.4)
Pregnancy period 27 (9.28) 20 (7.04) 0.33 1.4 (0.8–2.6) 1.3 (0.7–2.6) 1.5 (0.7–2.9)
First Trimester 14 (4.81) 9 (3.17) 0.31 1.6 (0.7–3.8) 1.6 (0.6–4.1) 1.7 (0.6–4.4)
Second Trimester 18 (6.19) 14 (4.93) 0.51 1.3 (0.7–2.8) 1.3 (0.6–3.0) 1.4 (0.6–3.2)
Third Trimester 12 (4.12) 12 (4.23) 0.95 1.0 (0.5–2.4) 1.0 (0.4–2.5) 1.1 (0.4–2.7)
B2AR β2-adrenergic receptor; ASD autism spectrum disorder; OR odds ratio; CI confidence interval
aThe reference group had no exposure to any B2AR agonists or mimics from 30 days before conception through delivery
bChi-square test
cOdds ratios were adjusted for maternal education, maternal age, birth type, gestational age, parity, birth hospital, birth year, and sex
dOdds ratios were adjusted for the variables listed above in addition to asthma and preterm labor indications
eOnly five case mothers and seven control mothers had exposure to any B2AR agonist during each trimester of pregnancy
J Neurodevelop Disord (2011) 3:307–315 311elevated. We also estimated the effect of terbutaline exposure
in a subsample restricted to those women with an indicating
medical condition (asthma or preterm labor). In this
subsample, terbutaline exposure for >2 days (ORadj=5.6,
95% CI 0.9–34.1) or ≥2 weeks (OR=4.4, 95% CI 0.5–39.8)
in the third trimester remained associated with autism risk.
This estimate is not confounded by the effect of an indicating
condition, as all women included had an indication, but it is
possible that some of the effect is due to interaction between
indication and exposure.
All results were similar for the subset of children who
were singletons (data not shown). There were too few twins
to examine as a separate group. We repeated all analyses in
an expanded sample of women who had pharmacy benefits
in the third trimester, whether or not they had pharmacy
benefits throughout pregnancy (360 cases, 342 controls). In
this larger sample, the risk of ASD associated with
terbutaline exposure longer than 2 days was significantly
elevated after adjusting for indication and other covariates
(11 cases, 2 controls; ORadj=5.8; 95% CI, 1.2–28.4).
Results were similar for terbutaline exposure for ≥2 weeks
(six cases, one control; OR=5.8; 95% CI, 0.7–48.6).
Discussion
It is unlikely that a single exposure or insult is responsible
for all cases of biologically complex and clinically
heterogeneous neurodevelopmental disorders such as those
included in the autism spectrum. Yet, it is possible that
downstream cellular signaling abnormalities, such as
dysregulated cAMP generation, could act as a common
pathway in the development of these disorders in some
individuals (Connors 2008; Witter et al. 2009). With this in
mind, we investigated terbutaline and other B2AR agonists
since animal studies have shown that these drugs produced
functional changes in developing tissues and behaviors
comparable to those noted in autism.
In this case–control study, we did not find evidence of an
association between B2AR agonist exposure and autism
risk when considering either any B2AR exposure or
albuterol exposure specifically. We did find a suggestion
of an association between prolonged maternal exposure to
terbutaline for more than 2 days in the third trimester and
ASD risk, although the effect estimate was imprecise due to
the small sample size. We did not see an association for
second trimester exposure which is where most of the
animal studies have focused. This may have been due to the
fact that only two women had second trimester exposures to
terbutaline in our population. One previous report linked
prolonged terbutaline exposure during the second and third
trimesters to ASD concordance among 36 sets of dizygotic
autism twin pairs (Connors et al. 2005). Because twin
pregnancies are at high risk for exposure to tocolytics, a
dizygotic twin series provided an opportunity to explore a
potential association in a relatively small sample size.
However, twin pregnancies differ in many ways from
singleton pregnancies and the twin sample previously
studied was a clinical case series and not derived from a
population-based frame. In this investigation, we were able
to focus on the far larger group of singleton cases drawn
from a large KPNC-enrolled sampling frame. Further
review of our results also indicates that maternal treatment
with B2AR agonists during pregnancy does not explain
our previous observation of increased ASD risk among
asthmatic mothers (Croen et al. 2005)
Table 4 Adjusted ORs and 95% CIs for ASDs associated with duration of exposure to B2AR agonists during pregnancy
Exposure
a No. (%) Adjusted OR (95% CI)
b Adjusted OR (95% CI)
c
ASD case (n=291) Control (n=284)
Terbutaline
>2 Days
d 8 (2.75) 2 (0.704) 4.1 (0.8–22.4) 4.4 (0.8–24.6)
1–2 Days 24 (8.25) 19 (6.69) 1.0 (0.5–2.0) 1.0 (0.5–2.0)
Albuterol
>21 Days
e 14 (4.81) 11 (3.87) 1.3 (0.5–3.1) 1.4 (0.6–3.5)
≤21 Days 13 (4.47) 9 (3.17) 1.2 (0.5–3.1) 1.3 (0.5–3.4)
B2AR β2-adrenergic receptor; OR odds ratio; CI confidence interval
aThe reference group had no exposure to any B2AR agonists from 30 days before conception through delivery; cut-points for duration based on
distribution of length of exposure among control mothers
bOdds ratios were adjusted for maternal education, maternal age, birth type, gestational age, parity, birth hospital, birth year, and sex
cOdds ratios were adjusted for variables listed above in addition to asthma and preterm labor indications
dAll women with >2 days of exposure were exposed for this duration in the third trimester
e>21 Days of exposure occurred across multiple trimesters
312 J Neurodevelop Disord (2011) 3:307–315Although this study employs a larger study population
than previous reports investigating B2AR exposure and
autism risk in human populations, our analysis still
generated statistically imprecise effect estimates. For
measures of any exposure to all B2AR agonists, albuterol
or terbutaline, odds ratios point estimates were also small in
magnitude (below 2.0). For long-duration terbutaline
exposure in the third trimester where a large odds ratio
point estimate was seen, the proportion exposed was very
small (<1% in the controls) and the resulting confidence
limits were quite wide. Larger study populations will be
needed to adequately investigate long-duration exposure.
This analysis had the advantage of relying on prospec-
tively collected information on prescribed medications
which allowed for examination of risk for specific periods
during pregnancy and duration of exposure. However, these
records document dispensed prescriptions and therefore
exposure could have been misclassified if women did not
take the medications as indicated. Although we controlled
for many potential confounding factors, including indica-
tors for preterm labor, the possibility that longer duration
treatment with terbutaline may in fact represent a marker
for an underlying pathogenic process (e.g., maternal stress
or inflammation) rather than a risk factor for ASD cannot
be completely ruled out.
ASD case status was determined by diagnoses
recorded in medical records. A subset of 50 cases was
also evaluated with the Autism Diagnostic Interview-
Revised (Lord et al. 1994) and the Autism Diagnostic
Observation Schedule-Generic (Lord et al. 2000)i na
previously published validation study (Croen et al. 2008).
Of these 50 cases, 94% met criteria for ASD on both
instruments and 100% met criteria on at least one. In
addition, it was reported that at least 90% of children with
an ASD diagnosis recorded in the KPNC electronic
databases had documentation consistent with a diagnosis
of autism based on Diagnostic and Statistical Manual of
Mental Disorders (fourth edition) criteria (Croen et al.
2008). In the analysis reported here, we were unable to
stratify cases into phenotypic subgroups based on severity
of ASD or other characteristics as the data in the medical
records were not sufficient to accurately and completely
make these distinctions. Evaluation of genotypic sub-
groups may also be important in fully understanding the
effects of maternal exposure to B2AR agonists. Of note,
variants at two polymorphic sites on the B2AR gene
whose function is believed to be related to increased
responsiveness of the receptor to ligand have been
associated preliminarily with autism risk (Connors et al.
2005;C h e s l a c k - P o s t a v ae ta l .2007). In our study, genetic
data were not available and there was no way to
investigate whether B2AR exposure effects might have
been stronger in subgroups defined by genotype.
The possibility of a large-magnitude association between
terbutaline exposure of more than 2 days in duration during
the third trimester and autism risk does have public health
implications. One or 2 days of treatment is consistent with
brief exposure as defined in a “Dear Colleague” letter sent
by the FDA in 1997 alerting practitioners, home healthcare
agencies, insurance carriers, and others that “the demon-
strated value of tocolytics in general is limited to an initial,
brief period of treatment, probably no more than 48–72 h”
(US Food and Drug Administration (FDA) and Nightingale
1997). More than 2 days of continued administration is
considered “maintenance” therapy. As indicated above,
more than half of the women in this category had exposures
for 2 or more weeks’ duration. There already is a
documented lack of evidence for safety and efficacy of
maintenance tocolysis (Larsen et al. 1986; The Canadian
Preterm Labor Investigators Group 1992; Higby et al. 1993;
Hudgens and Conradi 1993). Terbutaline’s ability to arrest
uterine contractions wanes within 48 h because the beta-2
receptors in the myometrium downregulate and desensitize
in response to continuous stimulation (Frambach et al.
2005). In addition, other factors that govern uterine
contractions are likely to provide a continuing stimulus
that is not overcome by B2AR agonists. In contrast to the
mature receptor forms found in the uterus, B2ARs in the
immature brain sensitize in response to sustained stimula-
tion by terbutaline, which leads to persistent activation and
abnormal downstream intracellular signaling in animals
(Slotkin and Seidler 2006).
In 2003, the American College of Obstetrics and
Gynecology published a practice bulletin for the manage-
ment of preterm labor, stating that “neither maintenance
treatment with tocolytic drugs nor repeated acute tocolysis
improve perinatal outcome; neither should be undertaken as
a general practice” (ACOG Practice Bulletin 2003). Should
prolonged exposure to terbutaline for more than 2 days
during pregnancy be associated with increased risk of ASD
this would be another important factor dissuading the use of
maintenance treatment with tocolytic drugs for the
management of preterm labor. Terbutaline is no longer
used to treat preterm labor at KPNC. However, surveys
of obstetric providers indicate that terbutaline is still
being used as a maintenance tocolytic in other medical
communities (Fox et al. 2008; Morgan et al. 2008).
Conclusion
Prenatal exposure to any B2AR occurred at a similar rate
among children with autism and control children. Asthma
treatment with B2AR agonists during pregnancy does not
explain our previous observation of increased ASD risk
among asthmatic mothers. There is a suggestion that
J Neurodevelop Disord (2011) 3:307–315 313maternal exposure to terbutaline for greater than 2 days
during the third trimester of pregnancy could be associated
with elevated autism risk—however, larger studies are
needed. Should this association be confirmed, it would
provide further contraindication to maintenance tocolysis
with B2ARs and also raise interesting questions about late
pregnancy mechanisms and exposures to be considered in
autism risk factor research.
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